文献速递妇科

晚期高级别与低级别浆液性上皮性卵巢癌患者的结局

Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
PubMed 文献 · Obstet Gynecol · 2017-01-01

基于美国国家癌症数据库2003至2011年的回顾性研究,纳入16854例高级别和755例低级别晚期(IIIC期和IV期)浆液性卵巢癌患者。低级别患者中位总生存期90.8个月,高级别患者40.7个月(P<.001)。在低级别患者倾向性评分匹配队列中,淋巴结清扫与改善生存相关,而辅助化疗与生存无显著相关。

要点

  • 低级别晚期浆液性卵巢癌中位总生存期90.8个月,高级别为40.7个月(P<.001)。
  • 低级别患者匹配队列中,接受化疗者中位总生存期88.2个月,未接受化疗者95.9个月(P=.7)。
  • 低级别患者匹配队列中,接受淋巴结清扫者中位总生存期106.5个月,未接受者58个月(P<.001)。

核心结论

  • 与高级别浆液性卵巢癌相比,低级别浆液性卵巢癌与改善的生存相关。
  • 在晚期低级别浆液性卵巢癌患者中,淋巴结清扫而非辅助化疗与改善的生存相关。

研究设计与样本

  • 回顾性研究,使用美国国家癌症数据库,纳入2003至2011年诊断为1级或3级晚期(IIIC期和IV期)浆液性卵巢癌的患者。
  • 共识别16854例(95.7%)高级别浆液性卵巢癌患者和755例(4.3%)低级别浆液性卵巢癌患者。
  • 采用Kaplan-Meier法分析分级对生存的影响,Cox比例风险模型比较预测结局的因素,低级别患者中采用倾向性评分匹配比较接受与未接受化疗及淋巴结清扫者的全因死亡率。

主要发现

  • 高级别患者中位总生存期为40.7个月,低级别患者为90.8个月(P<.001)。
  • 低级别倾向性评分匹配队列中,接受化疗的140例患者中位总生存期为88.2个月,未接受化疗的140例为95.9个月(P=.7)。
  • 淋巴结清扫倾向性匹配队列中,接受淋巴结清扫的202例患者中位总生存期为106.5个月,未接受淋巴结清扫的202例为58个月(P<.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare outcomes of women with advanced-stage low-grade serous ovarian cancer and high-grade serous ovarian cancer and identify factors associated with survival among patients with advanced-stage low-grade serous ovarian cancer. METHODS: A retrospective study of patients diagnosed with grade 1 or 3, advanced-stage (stage IIIC and IV) serous ovarian cancer between 2003 and 2011 was undertaken using the National Cancer Database, a large administrative database. The effect of grade on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model. Among women with low-grade serous ovarian cancer, propensity score matching was used to compare all-cause mortality among similar women who underwent chemotherapy and lymph node dissection and those who did not. RESULTS: A total of 16,854 (95.7%) patients with high-grade serous ovarian cancer and 755 (4.3%) patients with low-grade serous ovarian cancer were identified. Median overall survival was 40.7 months among high-grade patients and 90.8 months among women with low-grade tumors (P<.001). Among patients with low-grade serous ovarian cancer in the propensity score-matched cohort, the median overall survival was 88.2 months among the 140 patients who received chemotherapy and 95.9 months among the 140 who did not receive chemotherapy (P=.7). Conversely, in the lymph node dissection propensity-matched cohort, median overall survival was 106.5 months among the 202 patients who underwent lymph node dissection and 58 months among the 202 who did not (P<.001). CONCLUSION: When compared with high-grade serous ovarian cancer, low-grade serous ovarian cancer is associated with improved survival. In patients with advanced-stage low-grade serous ovarian cancer, lymphadenectomy but not adjuvant chemotherapy was associated with improved survival.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gockley A, Melamed A, Bregar AJ, et al. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol. 2017. PMID: 28178043. doi:10.1097/AOG.0000000000001867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。